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Abstract
Background: Overexpression of Neutral Endopeptidase (NEP) has been reported in metastatic carcinomas, implicating
NEP in tumor progression and suggesting a role for NEP inhibitors in its treatment. We investigated the role of NEP
expression in the clinical progression of cutaneous melanoma.
Methods: We screened 7 melanoma cell lines for NEP protein expression. NEP-specific siRNA was transfected into the
lines to examine the role of gene transcription in NEP expression. Immunohistochemistry was done for 93 specimens
and correlated with clinicopathologic parameters. Thirty-seven metastatic melanoma specimens were examined for NEP
transcript expression using Affymetrix GeneChips. In a subset of 25 specimens for which both transcript and protein
expression was available, expression ratios were used to identify genes that co-express with NEP in GeneChip analysis.
Results: NEP was overexpressed in 4/7 human melanoma cell lines, and siRNA knock-down of NEP transcripts led to
downregulation of its protein expression. NEP protein overexpression was significantly more common in metastatic
versus primary tumors (P = 0.002). Twelve of 37 (32%) metastatic tumors had increased NEP transcript expression, and
an association was observed between NEP transcript upregulation and protein overexpression (P < 0.0001). Thirty-eight
genes were found to significantly co-express with NEP (p < 0.005). Thirty-three genes positively correlated with NEP,
including genes involved in the MAP kinase pathway, antigen processing and presentation, apoptosis, and WNT signaling
pathway, and 5 genes negatively correlated with NEP, including genes of focal adhesion and the notch signaling pathways.
Conclusion: NEP overexpression, which seems to be largely driven by increased transcription, is rare in primary
melanoma and occurs late in melanoma progression. Functional studies are needed to better understand the mechanisms
of NEP regulation in melanoma.
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Background
Neutral endopeptidase (NEP, also known as CD10, MME,
CALLA) is a 90–100 kDA cell surface peptidase that inac-
tivates a variety of physiologically active peptides. Altered
NEP expression has been shown to play a role in many
non-neoplastic [1-3] and neoplastic disaeases [4-8]. In
many tumors, such as prostate and small-cell lung cancer,
NEP is thought to act as a tumor suppressor, as its expres-
sion is down-regulated with tumor progression [4,5]. In
this regard, we have previously shown that loss of NEP in
cultured prostate cancer cells stimulates cell proliferation
and migration [9]. We also demonstrated that complete
loss of NEP expression was independently associated with
prostate cancer recurrence after surgery [6].
Data from other tumor types, however, reveal a more
complex role of NEP in neoplastic disorders. Several inde-
pendent studies have shown a correlation between
increased NEP, rather than decreased or absent expres-
sion, and tumor progression [7,8,10]. An association
between NEP expression and increased proliferation was
reported in aggressive non-Hodgkin lymphoma [8], and
increased NEP expression has been shown to correlate
with invasion and liver metastasis in colorectal carcinoma
[7,10]. Other investigators have demonstrated that tumor-
specific expression of NEP in stromal cells may facilitate
invasion and metastatic progression in gastric, breast and
colorectal carcinomas [11-13].
The association between increased NEP expression and
melanoma progression is of particular therapeutic interest
given the availability of NEP inhibitors [14,15]. In our
study, we screened several melanoma cell lines for NEP
protein expression and examined increased transcription
as a possible mechanism of its protein overexpression. We
further examined NEP transcription and protein expres-
sion in a well-characterized cohort of melanoma patients.
We then explored the Genechip data to determine if there
were other genes whose expression correlated with NEP
expression. Both our in-vitro and in-vivo data suggest that
NEP overexpression is largely driven by increased tran-
scription. We also demonstrate that NEP overexpression is
a rare event in primary melanoma and occurs more com-
monly in metastatic melanoma. NEP overexpression did
not seem to have a strong prognostic value in our study
cohort. Functional studies are underway to determine the
mechanisms of NEP regulation in melanoma.
Methods
Protein extraction, immunoprecipitation, and Western 
blot analysis
Seven human metastatic melanoma cell lines were stud-
ied, including SK-MEL-19, -23, -29, -85, -100, -197 (gifts
of Dr. Alan Houghton) and Mewo (American Type Cul-
ture Collection, Manassas, VA). The SK-MEL cell lines
were cultured in Dulbecco's modified Eagle's medium
supplemented with 10% fetal bovine serum, 2 mM L-
glutamine and 1% penicillin/streptomycin. The Mewo
cell line was maintained in modified Eagle's medium con-
taining 10% Fetal Bovine Serum. All cell lines were rou-
tinely grown at 37°C under 5% CO2. The cells were
passed two times weekly in order to keep them in the
exponential growth phase. Cells were washed with cold
PBS and then lysed with an ice-cold buffer (pH 7.0) con-
taining 10 mM Tris-HCl (pH 7.5), 1 mM EDTA, 400 mM
NaCl, 10% glycerol, 0.5% NP40, and protease and phos-
phatase inhibitors. Lysates were placed on ice for 20 min-
utes before clarification by centrifugation. Protein
determinations were performed using the Bradford
method (Bio-Rad Laboratories, Hercules, CA). Twenty-
five to 50 μg of each sample were fractionated by SDS-
PAGE and transferred to Immobilon-P membranes (Mill-
ipore, Bedford, MA). Membranes were blocked with 8%
nonfat dry milk, 0.1% Tween 20 in PBS, and probed with
the anti-NEP mouse monoclonal antibody, NCL-CD-10-
270 (1:100, NovaCastra Laboratories Ltd., Newcastle
upon Tyne, UK). Protein loading was confirmed using the
goat anti-Ran monoclonal antibody (SC-1156, 1:200,
Santa Cruz Biotechnology). Bands were visualized using
the following horseradish peroxidase-conjugated second-
ary antibodies: anti-mouse (SC-2055, 1:2000, Santa Cruz
Biotechnology), and anti-goat (SC-2020, 1:4,000, Santa
Cruz Biotechnology) and the SuperSignal West Pico
chemiluminescent substrate (Pierce, Rockford, IL).
NEP siRNA transfection
Two million cells were transfected with 10 ug of siRNA
(Smartpool from Dharmacon Research, Inc., Lafayette,
CO) directed against NEP, or control non-specific siRNA
using the Amaxa Nucleofector system. Program U-20 was
selected for the SK-MEL-19 cell line and A-23 for the
Mewo cell line. Buffers used for the Nucleofecter were
NHEM solution for SK-MEL-19 and V solution for Mewo.
Post-transfected cells were transferred to 0.5 ml pre-
warmed RPMI1640 medium for 10 minutes at 37°C in a
CO2 incubator, and then seeded at 3.2 × 105/well in 24
well plates. Cells were incubated in a humidified 37°C
CO2 incubator for 48 hours. For each cell line, triplicate
transfections were conducted on the same day.
Patient characteristics
The study cohort consisted of 84 melanoma patients iden-
tified through the Interdisciplinary Melanoma Coopera-
tive Group database at the New York University (NYU)
School of Medicine (39 females, 45 males, mean age 58.5
± 18.1 years). Ninety-three specimens from 84 patients
were used for immunohistochemistry, and 37 specimens
from 32 patients were used for transcript expression anal-
ysis. Of these, 25 specimens from 22 patients were ana-
lyzed by both methodologies based on correspondingJournal of Translational Medicine 2007, 5:2 http://www.translational-medicine.com/content/5/1/2
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paraffin tissue availability. The Interdisciplinary
Melanoma Cooperative Group has been enrolling
patients since September 2002. Those patients with either
follow-up of at least 2 years and/or available fresh tissue
samples for microarray gene expression analysis were
selected for this study. The study was approved by the
NYU Institutional Review Board and all patients signed
informed consent before enrollment. Relevant clinico-
pathologic, demographic and survival data were recorded
for all patients.
Microarray gene expression analysis
NEP transcript expression was assessed using Affymetrix
U133Plus2.0 GeneChips on all available fresh tumor tis-
sue specimens, which included 37 metastatic melanoma
specimens obtained from 32 patients (3 patients had 2
metastases and 1 patient had 3 metastases included). Tis-
sue was collected at time of surgery for metastatic disease,
and placed in at least 10 volumes of RNAlater (Qiagen) at
4°C overnight, then stored at -80°C. Whole RNA was
extracted from the tissue using the RNeasy Mini Kit from
Qiagen. RNA was quantified by spectrophotometric
assessments at 260/280 nm, and RNA quality was
assessed by RNA 6000 Nano Assay using an Agilent 2100
Bioanalyzer (Agilent Technologies). Double stranded
cDNA synthesis was performed using a SuperScript dou-
ble-stranded cDNA synthesis kit from Invitrogen. In-vitro
transcription of biotin-labeled cRNA probes was done
using an IVT labeling kit (Affymetrix) following the kit's
instructions. The cRNA probes were chemically frag-
mented using a fragmentation buffer (Affymetrix), and
fragmented biotin-labeled cRNA was hybridized on
Affymetrix Human Genome U 133 Plus 2.0 chips, in the
Rockefeller University Genomics Core lab. The raw micro-
array data files were analyzed using BioConductor [16]
packages under R [17]. Data were normalized using the
robust multi-array average (RMA)[18] algorithm. Gene
expression ratios between each tumor specimen and the
lymph node control were calculated. Ratios greater than 2
were considered over expressed, otherwise they were con-
sidered as normal/under-expressed.
NEP transcript expression was analyzed in metastatic
melanoma samples according to the absolute call values
assigned by the chip reader, as well as in comparison to
normal lymph node tissue. The chip reader cutoff corre-
sponded to an intensity of 110–130, and the intensity of
normal lymph node tissue for NEP transcription was 338.
We thus used normal lymph node for comparison as a
more stringent control, since the germinal proliferating
centers of normal lymph node tissue displayed NEP
expression on immunohistochemistry and the majority of
the metastatic specimens studied were lymph node tis-
sues. The use of normal lymph node tissue as a control in
a similar setting was recently described by another group
[19]. Increased NEP transcript levels were defined as
greater than 2-fold increase of the absolute expression
compared to NEP transcript expression in normal lymph
node tissue. Comparison of NEP transcript regulation
between metastatic melanoma and primary melanoma
tissues was not feasible, since at our institution, primary
melanomas are not available as frozen specimens; instead
they are all formalin fixed after removal for diagnostic
purposes.
For the 25 specimens for which we had both transcript
and protein expression data, we identifed genes/probes
that co-express with NEP by ranking each probe through
multiple criteria using their expression ratios. First, we cal-
culated the correlation of expression ratios between each
probe and NEP using Pearson correlation coefficient,
where NEP expression was defined as the average of two
NEP probes that gave similar results. Secondly, the expres-
sion ratios were dichotomized based on the over-expres-
sion criteria. The correlation of the dichotomized
expressions between each gene and the NEP was calcu-
lated using Kendall's method. Adding this criterion
allowed for down-weighting genes that have similar
expression pattern as NEP but are largely over-expressed
or normal/under-expressed based on our over-expression
criteria. Thirdly, we compared the expressions between
the NEP over-expressed and NEP normal/under-expressed
subjects for each gene using Wilcoxon rank sum test.
Overall ranks of the genes were calculated by summing up
the ranks based on the two correlations and the p-values
from the Wilcoxon rank sum test. To ensure the expres-
sions between the NEP over-expressed and NEP normal/
under-expressed subjects differ and have relatively small
variation, we also employed the criteria that the p-value
from the t-test need to be less than 0.005.
Immunohistochemical analysis and scoring
Ninety-three specimens from 84 patients were examined
for NEP protein expression using an immunohistochemi-
cal assay, including 33 specimens from patients with Stage
I/II disease, and 60 specimens from patients with Stage
III/IV disease. Two patients had two primary melanoma
tumors included in the analysis, five patients had two
metastatic tumors included in the analysis, and one
patient had three metastatic tumors included in the anal-
ysis. All tissue sections were formalin fixed and paraffin
embedded. Expression of NEP was assessed using NCL-
CD-10-270 (NovaCastra Laboratories Ltd., Newcastle
upon Tyne, UK) at 1:25 dilution [20]. All immunohisto-
chemistry was performed on an automated immunos-
tainer (NexEs, Ventana Medical Systems) for
standardization of the assay and to minimize experimen-
tal variation in results. An antigen retrieval protocol for
enhancement of potentially masked epitopes was used.
Sections were immersed in boiling 0.01% citric acid (pHJournal of Translational Medicine 2007, 5:2 http://www.translational-medicine.com/content/5/1/2
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6.0) for twenty minutes under microwave treatment to
enhance antigen retrieval, allowed to cool, and incubated
with the NEP antibody overnight. Kidney sections dem-
onstrating strong NEP expression were used as positive
controls. Expression of NEP was scored by an attending
pathologist (E.V.), who was blinded to the patients' clini-
cal data. Scoring was based on the proportion of cells with
positive surface membrane and cytoplasmic staining.
Immunoreactivity was assessed on a continuous scale
with values ranging from undetectable levels (0%) to
homogenous staining (100%) of invasive melanoma
cells. We then classified tumors into three groups: focal
(undetectable-20%), moderate (20–60%) and diffuse
(60–100%). Moderate or diffuse expression was consid-
ered overexpression based on the strong association
between increased transcription and >20% (moderate and
diffuse) NEP protein expression. This molecular associa-
tion set >20% as the cut point for NEP protein overexpres-
sion.
Descriptive statistics were calculated for baseline demo-
graphic and clinicopathologic characteristics. Associa-
tions between NEP immunoreactivity and
clinicopathologic features were assessed by Fisher's exact
test, the chi-square test, or the Cochran-Armitage trend
test, as appropriate. Three survival outcome measures,
including overall survival (time from initial diagnosis of
melanoma to death), disease-free survival (time from ini-
tial diagnosis of melanoma to first recurrence), and sur-
vival after first recurrence (time from first recurrence to
death), were analyzed using the Kaplan-Meier method
with the log-rank test employed to evaluate associations
between NEP immunoreactivity status (overexpression
versus no overexpression) and survival outcome meas-
ures. Median follow-up time was computed as the median
survival time of the alive patients. All p-values are two-
sided with statistical significance evaluated at the 0.05
alpha level. Ninety-five percent confidence intervals (95%
CI) were calculated to assess the precision of the obtained
estimates. All analyses were performed in SAS Version 9.1
(SAS Institute, Inc., Cary, North Carolina) and Stata Ver-
sion 8.0 (Stata Corporation, College Station, Texas).
Results
NEP expression in cell lines and effect of NEP 
downregulation
We analyzed in-vitro NEP expression using 7 melanoma
cell lines. Four of 7 (57%) of the melanoma cell lines
overexpressed NEP with the maximum level of expression
observed in the MeWo and SK-MEL-19 cell lines. To inves-
tigate the role of gene transcription in NEP expression,
NEP specific siRNA was transfected into the SK-MEL-19
and MeWo cell lines. This led to a marked reduction in
NEP protein in the 2 cell lines tested (Figure 1).
NEP protein expression in primary melanoma
NEP protein expression was examined in 33 primary
melanoma tumor specimens from 31 patients with Stage
I/II disease. The median tumor thickness for primary
tumors was 1.0 mm (range 0.3–11.0 mm); with 17
tumors ≤ 1.0 mm, 13 tumors 1.01–4.0 mm, and 3 tumors
>4.0 mm in Breslow thickness. Of the 31 patients whose
primary melanomas were analyzed, 19 (61%) were Stage
I and 12 (39%) were Stage II, according to the 6th Edition
of the AJCC staging guidelines. Twenty (61%) tumors
were axial and 13 (39%) were on the extremities. Histo-
logic examination revealed 23 (70%) superficial spread-
ing type melanomas. The remainder were nodular (n = 5),
desmoplastic (n = 2), acral, lentigo maligna and indeter-
minate (n = 1 for each). Only 1 of the 33 tumors diffusely
overexpressed NEP. This was an 11.0 mm ulcerated acral
melanoma detected in a 69 year-old Caucasian man who
subsequently developed lymph node and liver metastases
before dying of disease three years after diagnosis. The
other primary melanomas were completely negative for NEP
expression.
NEP protein expression in metastatic melanoma
We next examined NEP expression in 60 melanoma
tumors from 53 patients with Stage III/IV disease (27
lymph node metastases, 19 skin or subcutaneous metas-
tases, 8 visceral metastases and 6 biopsies from primary
lesions in patients with Stage III disease). Eighteen of the
60 (30%) specimens showed overexpression of NEP,
which was significantly different compared to the primary
tumor rate of 1/33 (3%) (P = 0.002 by Fisher's exact test).
Table 1 displays the distribution of cases tested by immu-
nohistochemistry. Figures 2 and 3 illustrate representative
melanoma cases showing focal NEP expression (Figure 2),
NEP transcript downregulation in melanoma cell lines Figure 1
NEP transcript downregulation in melanoma cell 
lines. Melanoma SK-MEL 19 (1a) and MeWo (1b) cell lines 
were transfected with 10 ug of control siRNA (left column) 
and NEP siRNA (right column) in one million cells. The cells 
were harvested 48 hours post-transfection. Following siRNA 
transfection, there was decreased expression of NEP in both 
cell lines. RAN served as a control.Journal of Translational Medicine 2007, 5:2 http://www.translational-medicine.com/content/5/1/2
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and diffuse NEP overexpression (Figure 3). There was a
trend towards increased NEP overexpression in visceral
metastases versus skin and lymph node metastases (57%
(4/7) of patients with visceral metastases, versus 40% (6/
15) and 24% (6/25) of patients with skin and lymph node
metastases, respectively, p = 0.08 by trend test). Clinico-
pathologic correlation with NEP overexpression in meta-
static melanoma samples revealed no significant
association between increased NEP expression and age
(27% of subjects ≤ 65 years-old overexpressed NEP versus
40% of subjects >65 years-old, p = 0.34) or gender (40%
of females versus 25% of males overexpressed NEP,
p = 0.24).
NEP protein expression in metastatic melanoma: 
correlation with survival endpoints
There were no statistically significant differences in sur-
vival endpoints based on NEP protein expression, how-
ever there was a nonsignificant trend towards shorter
survival among patients overexpressing NEP. Median
overall survival time was 2.5 years shorter for metastatic
melanoma patients who overexpressed NEP compared to
metastatic melanoma patients not overexpressing NEP
[10.2 years (95% CI 4.7–15.7 years) versus 12.7 years
(95% CI 7.1–18.3 years) respectively, p = 0.74 by log-rank
test]. Patients with metastatic melanoma demonstrating
NEP overexpression also had a 2.2 year shorter median
disease-free survival time than metastatic melanoma
patients not overexpressing NEP [4.9 years (95% CI 1.3–
10.1 years) vs. 7.1 years (95% CI 2.2–10.3 years), respec-
tively, p = 0.74]. Finally, two-year post-recurrence survival
rates were 67% and 64% for subjects who overexpressed
NEP versus those who did not overexpress NEP, respec-
tively (p = 0.89 by log-rank test).
NEP protein expression correlated with NEP transcript 
upregulation
RNA transcript levels of metastatic tumors were deter-
mined using Affymetrix U133Plus2.0 GeneChips and cor-
related with immunohistochemical analysis of the same
tumor tissues. Twelve of 37 (32%) metastatic tumors (6 of
18 lymph node, 5 of 17 skin, and 1 of 2 visceral) had at
least two-fold increase of NEP transcripts in comparison
to normal lymph node tissue (range 0.09–8.77-fold, Fig-
NEP expression in melanoma by immunohistochemistry Figure 3
NEP expression in melanoma by immunohistochem-
istry. Metastatic melanoma showing diffuse NEP expression 
(red stain) (20×).
Table 1: NEP Protein Expression in Melanoma Specimens Tested by Immunohistochemistry
Disease Stage: Specimens tested (n) NEP overexpression (n) NEP overexpression (%)
Primary 33 1 3%
Metastatic
Lymph Node 27 7 26%
Skin/Subcutaneous 19 6 32%
Visceral 8 4 50%
Primary biopsy from metastatic patients 6 1 17%
Total 60 18 30%
Immunohistochemical detection of NEP expression in  melanoma Figure 2
Immunohistochemical detection of NEP expression 
in melanoma. Metastatic melanoma showing focal expres-
sion of NEP (red stain) (20×).Journal of Translational Medicine 2007, 5:2 http://www.translational-medicine.com/content/5/1/2
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ure 4). Of the 37 metastatic melanoma tumors tested for
NEP transcript expression, 25 were also examined for NEP
protein expression using immunohistochemistry, includ-
ing 12 lymph node, 11 subcutaneous and 2 visceral
metastases. Table 2 shows the transcript and protein
expression for these 25 tumor specimens. Correlation of
NEP transcript and protein levels revealed that there was a
statistically significant association between increased NEP
transcript and NEP protein overexpression, in which all
(8/8) of tumors that had greater than 2-fold (range 2.16–
8.77–fold) increase in NEP transcripts displayed protein
overexpression, whereas only 12% (2/17) of tumors with
normal or decreased transcript levels overexpressed NEP
(p < 0.0001 by Fisher's exact test). Analysis of these data
using the absolute call values of the genechip data
revealed similar results (data not shown).
Identification of genes that co-express with NEP
To identify genes/probes that co-express with NEP, we
analyzed the geneprobe data from the 25 specimens for
which we had both transcript and protein expression data.
Among the top 100 gene probes in overall ranks, 41
probes from 38 genes (besides two NEP probes) had their
t-test p-values less than 0.005 and were considered co-
expressing with NEP. Within these selected genes, 33 were
positively correlated with NEP expression (Table 3) and 5
were negatively correlated with the NEP expression
(Table 4).
Discussion
We investigated the clinical relevance of altered NEP
expression in a well-characterized cohort of melanoma
patients. We chose to examine NEP expression in
NEP transcript expression analysis Figure 4
NEP transcript expression analysis. Results of gene transcript expression analysis of NEP in 37 metastatic melanoma sam-
ples, expressed as a ratio of NEP expression in normal lymph node tissue. Twelve of 37 samples show at least 2-fold increased 
gene expression.Journal of Translational Medicine 2007, 5:2 http://www.translational-medicine.com/content/5/1/2
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melanoma since there is growing evidence that upregula-
tion of its expression may relate to tumor progression.
Furthermore, the availability of NEP inhibitors [14,15]
makes NEP a potential therapeutic target. We first
screened several human melanoma cell lines to explore in-
vitro the frequency of the NEP protein expression before
utilizing more precious clinical specimens linked to
extended follow up information. We also examined
increased transcription as a possible mechanism of NEP
protein overespression. Our study reveals that NEP over-
expression is common in patients with metastatic
melanoma and is related to increased transcription. It also
suggests an association with visceral spread of disease that
requires validation in a larger dataset.
While our initial plan was to explore the correlation
between NEP overexpression in primary melanoma and
clinicopathological parameters of poor outcome and sur-
vival, we limited our study to only 33 primary tumors due
the very low frequency of altered NEP expression in this
particular clinical setting. Thirty-two of the 33 cases
showed undetectable NEP expression. The only primary
tumor that showed NEP overexpression (diffuse expres-
sion) was an acral melanoma, which has already been
established as having distinct biological and genetic
underpinnings compared to non-acral cutaneous
melanoma [21]. We decided, therefore, to conserve the
utilization of tissues from primary cases and limited our
report to 33 cases. This low rate of overexpression seen in
primary lesions is lower than two studies that reported a
frequency of 20%[22,23]. The discordance is most likely
attributable to the fact that previous studies included a
greater number of thick primary tumors [22]. The rela-
tively small number of thick melanomas in our study
cohort reflects the nationwide trend towards thinner
lesions at the time of diagnosis over the last few decades
[24]. In addition, we used a rigorous cutoff point of 20%
in determining overexpression, which is supported by the
significant correlation between ≥2 fold increase in NEP
transcripts and overexpression of its protein using immu-
nohistochemistry. Previous studies defined NEP overex-
pression as any expression more than 1% or 10% staining
[22,23]. We also found that there is a trend towards
increased NEP expression in visceral metastases, suggest-
ing that NEP overexpression may be related to certain bio-
logical behaviors of tumor spread. However, our ability to
better define this relationship is limited by the availability
of tumor tissue from visceral metastases, as most patients
do not undergo biopsies of these tumors as part of their
standard clinical care. Thus most available metastatic
samples are skin and lymph node metastases. Neverthe-
less, the observation that NEP overexpression is correlated
with visceral metastases has been previously reported in
colorectal cancer [7]. In that study, NEP overexpression
was an independent predictor of liver metastasis (n =
505). These data suggest that increased NEP expression
relates to hematologic metastasis of a subset of solid
tumors.
We next examined whether NEP expression correlated
with patient survival. We analyzed three measures of sur-
vival, including overall survival time from initial
melanoma diagnosis, time from initial diagnosis to first
recurrence, and survival time after first recurrence. No sig-
nificant differences were detected for any of the survival
measurements. Previously published work, based on find-
ings of only two patients, suggested that patients with
NEP-positive metastases may have shorter survival times
than those with NEP-negative metastases [23]. A larger
sample size with extended follow-up is needed to validate
these findings. In addition, the inclusion of more visceral
metastases might be considered.
We found a strong correlation between increased NEP
transcription and its protein overexpression, suggesting
that the protein accumulation is secondary to increased
production (as is the case with other oncogenes such as
epidermal growth factor receptor and cyclin D1 in lung
and esophageal cancer, respectively) rather than an
increase in protein half-life or decrease in protein degra-
dation [25-27]. Of note, our in vitro screening was not
meant to appropriately address the functional mechanism
Table 2: Correlation between NEP Transcript and Protein 
expression in 25 melanoma specimens
Specimen Transcript fold change Protein Expression
18 . 7 7 D i f f u s e
26 . 3 1 M o d e r a t e
35 . 0 5 D i f f u s e
44 . 6 6 D i f f u s e
54 . 0 8 D i f f u s e
63 . 2 9 D i f f u s e
73 . 1 7 D i f f u s e
82 . 1 6 D i f f u s e
91 . 8 6 F o c a l
10 1.74 Negative
11 1.65 Negative
12 1.43 Negative
13 1.20 Focal
14 0.89 Diffuse
15 0.77 Focal
16 0.65 Focal
17 0.51 Focal
18 0.49 Focal
19 0.48 Negative
20 0.38 Focal
21 0.37 Negative
22 0.34 Focal
23 0.30 Negative
24 0.28 Diffuse
25 0.27 NegativeJournal of Translational Medicine 2007, 5:2 http://www.translational-medicine.com/content/5/1/2
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Table 3: Genes that positively correlate with NEP
Gene Probe Gene Symbol corA* corB** p-value*** Gene Name
208469_s_at EGFL8 0.819 0.852 0.00006 EGF-like-domain, multiple 8
209826_at PPT2 0.729 0.861 0.00008 palmitoyl-protein thioesterase 2
226270_at EXOC2 0.659 0.751 0.00006 exocyst complex component 2
201537_s_at DUSP3 0.632 0.79 0.00006 dual specificity phosphatase 3 (vaccinia virus phosphatase VH1-related)
223057_s_at XPO5 0.665 0.706 0.00018 exportin 5
209238_at STX3A 0.729 0.747 0.00048 syntaxin 3A
200824_at GSTP1 0.729 0.765 0.00086 glutathione S-transferase pi
208899_x_at ATP6V1D 0.618 0.673 0.00035 ATPase, H+ transporting, lysosomal 34 kDa, V1 subunit D
223113_at HSPC196 0.718 0.765 0.00135 NA
209490_s_at PPT2 0.514 0.737 0.00012 palmitoyl-protein thioesterase 2
200692_s_at HSPA9B 0.557 0.667 0.00035 heat shock 70 kDa protein 9B (mortalin-2)
223056_s_at XPO5 0.527 0.738 0.00048 exportin 5
202475_at NIFIE14 0.514 0.781 0.00035 NA
227124_at NA 0.665 0.753 0.00147 NA
203723_at ITPKB 0.718 0.646 0.00086 inositol 1,4,5-trisphosphate 3-kinase B
200924_s_at SLC3A2 0.527 0.697 0.0009 solute carrier family 3 (activators of dibasic and neutral amino acid transport), 
member 2
211968_s_at HSP90AA1 0.43 0.831 0.00006 heat shock protein 90 kDa alpha (cytosolic), class A member 1
219526_at C14orf169 0.49 0.615 0.00035 chromosome 14 open reading frame 169
218465_at TMEM33 0.729 0.697 0.00307 transmembrane protein 33
200691_s_at HSPA9B 0.632 0.653 0.00243 heat shock 70 kDa protein 9B (mortalin-2)
212793_at DAAM2 0.618 0.566 0.00064 dishevelled associated activator of morphogenesis 2
201089_at ATP6V1B2 0.618 0.601 0.0019 ATPase, H+ transporting, lysosomal 56/58 kDa, V1 subunit B2
218305_at IPO4 0.43 0.683 0.00035 importin 4
32836_at AGPAT1 0.618 0.56 0.00113 1-acylglycerol-3-phosphate O-acyltransferase 1 (lysophosphatidic acid 
acyltransferase, alpha)
201195_s_at SLC7A5 0.43 0.642 0.00048 solute carrier family 7 (cationic amino acid transporter, y+ system), member 5
202088_at SLC39A6 0.418 0.825 0.00064 solute carrier family 39 (zinc transporter), member 6
205512_s_at PDCD8 0.527 0.604 0.00307 programmed cell death 8 (apoptosis-inducing factor)
1554679_a_at LAPTM4B 0.665 0.545 0.0019 lysosomal associated protein transmembrane 4 beta
226101_at PRKCE 0.514 0.542 0.00064 protein kinase C, epsilon
214359_s_at HSP90AB1 0.402 0.651 0.00035 heat shock protein 90 kDa alpha (cytosolic), class B member 1
239406_at ZNF193 0.49 0.642 0.00387 zinc finger protein 193
204015_s_at DUSP4 0.665 0.6 0.00483 dual specificity phosphatase 4
201771_at SCAMP3 0.43 0.583 0.00147 secretory carrier membrane protein 3
203914_x_at HPGD 0.618 0.561 0.00483 hydroxyprostaglandin dehydrogenase 15-(NAD)
211373_s_at PSEN2 0.43 0.542 0.0019 presenilin 2 (Alzheimer disease 4)
220272_at BNC2 0.659 0.575 0.00736 basonuclin 2
*corA = calculated correlation dichotomized based on ratio to lymph node
**corB = Pearson correlation
***p-value for w-stat: p-value for Wilcoxan rank-sum test
Table 4: Genes that negatively correlate with NEP
Gene Probe Gene Symbol corA* corB** p-value*** Gene Name
203865_s_at ADARB1 -0.542 -0.566 0.00483 adenosine deaminase, RNA-specific, B1 (RED1 homolog rat)
203324_s_at CAV2 -0.601 -0.534 0.0043 caveolin 2
226899_at UNC5B -0.659 -0.479 0.00064 unc-5 homolog B (C. elegans)
227162_at ZBTB26 -0.385 -0.541 0.00008 zinc finger and BTB domain containing 26
225923_at VAPB -0.487 -0.518 0.00307 VAMP (vesicle-associated membrane protein)-associated protein B and C
*corA = calculated correlation dichotomized based on ratio to lymph node
**corB = Pearson correlation
***p-value for w-stat: p-value for Wilcoxan rank-sum testJournal of Translational Medicine 2007, 5:2 http://www.translational-medicine.com/content/5/1/2
Page 9 of 10
(page number not for citation purposes)
of NEP regulation; it only served as a pilot experiment to
explore the frequency of NEP protein overexpression in
melanoma and the role of transcription in its up-regula-
tion before we embarked upon the utilization of more
precious human tissues.
We analyzed the microarray data to identify genes that co-
expressed with NEP. Interestingly, we found 33 genes that
positively correlated with NEP, and 5 genes that nega-
tively correlated with NEP. The genes that positively corre-
lated with NEP expression included those in the MAP
kinase pathway (n = 4), antigen processing and presenta-
tion (n = 4), apoptosis (n = 1), and WNT signaling path-
way (n = 1) [16]. Specifically, a number of the genes
identified have been found to be overexpressed in
melanoma and other cancers, including glutathione S
transferase pi, which is overexpressed in melanoma, and
is thought to play a role in melanoma drug resistance [28],
and lysosomal associated protein transmembrane 4 beta,
which is overexpressed in numerous solid tumors such as
hepatocellular carcinoma, lung cancer and colon cancer,
and has been shown to increase proliferation rates and
anchorage independent growth in tumor cell lines
[29,30]. Additionally, protein kinase C epsilon is
expressed in many human melanoma cell lines, and has
been hypothesized to be advantageous for in vivo growth
of melanoma cells [31,32].
The 5 genes that were negatively correlated with NEP
expression included genes involved in focal adhesion (n =
1) and the notch signaling pathway (n = 1) [16]. One of
these genes, Unc-5 homolog B, has been shown to be
down-regulated in multiple cancers, and appears to func-
tion as a tumor suppressor by mediating p53-dependent
apoptosis [33,34]. Another gene that negatively correlated
with NEP expression was caveolin 2, the expression of
which is decreased in breast cancer tissue when compared
to normal tissue and is correlated with hormone receptor
status [35]. Overall, NEP expression appears to correlate
with a number of important pathways in tumor growth
and development, and further investigations are needed
to determine whether NEP plays a causal role in these rela-
tionships, or is upregulated as a secondary effect of tumor
growth.
In conclusion, we demonstrated that NEP expression
relates to the progression of melanoma from primary to
metastatic disease, and may highlight biological differ-
ences in the pattern of spread of metastatic disease. More
functional investigations are needed to further under-
stand the mechanism and role of NEP expression in
melanoma progression.
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